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Abstract 
Spinal muscular atrophy (SMA) is a devastating infantile genetic disorder caused by the loss of 
survival motor neuron (SMN) protein that leads to premature death due to loss of motor neurons 
and muscle atrophy. The approval of an antisense oligonucleotide (ASO) therapy for SMA was 
an important milestone in SMA research, however, effective next generation therapeutics will 
likely require combinatorial SMN-dependent therapeutics and SMN-independent disease 
modifiers. A recent cross-disease transcriptomic analysis identified Stathmin-1 (STMN1), a 
tubulin depolymerizing protein, as a potential disease modifier across different motor neuron 
diseases, including SMA. Here, we investigated whether viral-based delivery of STMN1 
decreased disease severity in a well-characterized SMA mouse model. Intracerebroventricular 
delivery of scAAV9-STMN1 in SMA mice at P2 significantly increased survival and weight gain 
compared to untreated SMA mice without elevating Smn levels. scAAV9-STMN1 improved 
important hallmarks of disease, including motor function, NMJ pathology, and motor neuron cell 
preservation. Furthermore, scAAV9-STMN1 treatment restored microtubule networks and 
tubulin expression without affecting tubulin stability. Our results show that scAAV9-STMN1 
treatment improves SMA pathology possibly by increasing microtubule turnover leading to 
restored levels of stable microtubules. Overall, these data demonstrate that STMN1 can 
significantly reduce the SMA phenotype independent of restoring SMN protein and highlight the 
importance of developing SMN-independent therapeutics for the treatment of SMA.  
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Introduction  
Spinal muscular atrophy (SMA) is an infantile genetic disorder that causes the loss of spinal 
motor neurons and leads to progressive muscle atrophy, paralysis, and eventually premature 
death. SMA is caused by reduced levels of survival motor neuron (SMN) protein due to 
homozygous deletion of the SMN1 gene (1). While SMN protein is encoded by both SMN1 and 
SMN2, only SMN1 produces 100% SMN protein (2-4). In contrast, SMN2 carries a C to T 
transition in exon 7 that disrupts an exonic splicing enhancer, causing the alternative splicing of 
the SMN2 exon 7 transcript leading to ~10% full-length and ~90% of a truncated and 
dysfunctional SMN7 protein  (4, 5). Due to the low levels of SMN protein produced by SMN2, 
and the correlation between disease severity and SMN levels (6, 7), SMN2 is considered a 
fundamental disease modifier. Thus, an attractive therapeutic approach for SMA is to increase 
SMN levels by targeting SMN2 exon 7 inclusion. The first SMA approved drug, SpinrazaTM, 
employs this mechanistic approach to increase production of the full-length SMN transcript from 
SMN (8). The most recent FDA approved therapeutic, Zolgensma, in contrast, employs a gene 
replacement approach in order to restore SMN expression (9). However, continuing efforts 
should be made to identify alternative therapeutics that could potentially be combined to target a 
wider range of SMA patients and disease manifestations. 
Current therapeutics in clinical trials for SMA include SMN viral gene replacement (10), 
modulation of SMN2 splicing (11-14), increased SMN protein stability (15-19), SMN 
independent neuroprotectants (20), and muscle activators (21). However, current data from 
clinical trials and animal model studies indicate that SMN-dependent or SMN-independent 
strategies alone might not be sufficient to fully prevent or reverse SMA pathogenesis (22-24), 
therefore it is important to explore alternative approaches that could extend the therapeutic 
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window or increase the patient population that responds to SMN-targeting therapeutics. 
Combinatorial approaches are currently being examined in SMA mouse models. Plastin-3 
(PLS3), a potent disease modifier identified in discordant SMA families (25), significantly 
improved disease phenotype when combined with a sub-optimal antisense oligonucleotide 
(ASO) treatment over treatment of PLS3 or ASO alone (26-28) in animal models of SMA. 
Similarly, treatment of a severe SMA mouse model with Azithromycin, an FDA approved read-
through drug, in combination with a sub-optimal ASO dose significantly improved disease 
phenotype over either treatment alone (29). An important pipeline for complementary therapeutic 
pathways revolves around the identification of potent disease modifiers.  
Although SMN is ubiquitously expressed, a key feature of SMA that is not fully 
understood is the selective pathology within motor neurons (30). A major step forward in the 
understanding of selective vulnerability to pathology was the identification of specific motor 
units that are selectively resistant or vulnerable to pathology, as defined by denervation of the 
neuromuscular junction (NMJ) (31-33). Differentially vulnerable motor neuron populations have 
also been observed in other genetically distinct, but phenotypically similar, motor neuron 
diseases (MNDs) including amyotrophic lateral sclerosis (ALS) (34, 35), and spinal and bulbar 
muscular atrophy (SBMA) (36). This suggests that there may be specific genetic components 
that are intrinsic to particular motor neuron pools that confer resistance to pathology.  
Independent transcriptional profiling analyses of neurologically normal motor neurons, 
that are differentially vulnerable in each disease, revealed a large number of differentially 
regulated transcripts (34-40). Recently, comparisons of some of the independent transcriptional 
profilings across all three diseases generated a discrete list of uniformly dysregulated genes, a 
population that could be important genetic contributors to the pathology-resistant phenotype 
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(41). Alpha synuclein (SNCA) was one of these genes that was downregulated in each disease 
context. When SNCA was delivered to the central nervous system of SMA mice models via viral 
vector, SNCA expression significantly reduced disease severity, prolonged lifespan, and 
ameliorated NMJ pathology (41). Importantly, the initial basis for this screen was motor neuron 
pathology, and the demonstration that AAV9-SNCA significantly decreased motor neuron 
pathology validated the screen as a means to identify functionally relevant disease modifiers.  
Another important candidate in the list of top targets commonly downregulated across MNDs is 
Stathmin-1 (STMN1) (41). STMN1 is a ubiquitously expressed phosphoprotein involved in 
regulating microtubule dynamics by preventing protofilament lateral association (42). Given the 
involvement of STMN1 in neuronal cytoskeleton dynamics it is a target with high potential for 
modifying SMA phenotype. 
In this study, we investigated whether reintroduction of STMN1 could improve the 
phenotype and pathology in an intermediate mouse model of SMA. AAV-mediated delivery of 
STMN1 in SMA (Smn
2B/-
) mice significantly increased survival and birth-to-peak weight gain 
compared to untreated SMA mice. Motor function was also significantly improved indicated by 
improved time-to-right performance. NMJ pathology, a hallmark of SMA disease progression, 
was significantly reduced and accompanied with a reduced loss of lumbar motor neuron cell 
bodies. Collectively, this work emphasizes the importance of SMN-independent pathways and 
sheds light upon alternative mechanisms, including tubulin polymerization, that can contribute to 
the complex SMA pathology.  
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Results  
Strategy for identification of potential disease modifying genes. 
Identifying genes that have the potential to provide resistance or modify disease phenotypes can 
be challenging as gene expression patterns shift dramatically during the course of disease and 
development. To streamline the identification process, we previously utilized transcriptomic data 
derived from the analysis of differential gene expression between vulnerable and resistant motor 
neurons (41). Motor neuron cell bodies that were resistant or vulnerable to disease pathology 
were excised via laser microdissection and RNA was extracted (41). RNAseq identified 
differentially expressed genes, and an enriched list of candidate genes was identified by cross-
referencing to similar screens in related disease contexts, including ALS and SBMA. Lead 
candidates, including STMN1, were cloned and packaged into recombinant AAV9 virus and 
delivered to neonatal mouse models of SMA to test their efficacy at modifying disease 
phenotype (Figure 1). Stmn1 was found to be significantly downregulated in motor neurons that 
were vulnerable to pathology compared to resistant motor neuron, suggesting that its expression 
correlates with resistance to pathology.     
 
STMN1 treatment significantly extended survival and decreased disease severity in 
SMA mice. 
To investigate the potential of STMN1 to decrease the SMA phenotype, 1x10
11
 viral particles of 
scAAV9-STMN1 were delivered via a single intracerebroventricular (ICV) injection at postnatal 
day 2 (P2) to the intermediate Smn
2B/- 
SMA mouse model. Treatment resulted in a significant 
(28%) increase in mean survival of treated over untreated SMA mice, as well as an extension in 
the maximal life span from 24 days to beyond 50 days (Figure 2A). While an overall increase in 
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survival was observed, average weight gain did not increase in the treated cohort from birth to 
day 25 in treated SMA mice compared to untreated SMA mice (Figure 2B). However, the birth-
to-peak (overall percent increase) weight gain in STMN1 treated SMA mice was significantly 
increased compared to untreated SMA mice (Figure 2C). Moreover, overt phenotype appearance 
of scAAV9-STMN1 treated SMA mice (rightmost mouse) appeared improved as compared to 
SMA untreated mice (leftmost mouse) at P20 (Figure 2D). 
 We next investigated if STMN1 also improved motor function in SMA mice. Analysis of 
the righting reflex demonstrated that the percent of scAAV9-STMN1 treated SMA mice able to 
right themselves from P5 to P21 was similar to that of healthy controls, while the percent of 
untreated SMA remained below STMN1 the treated cohort from P7 to P21 (Figure 3A). 
Moreover, STMN1 treated mice showed a significant improvement in the average time to right 
from P6 to P16 compared to untreated SMA mice (Figure 3B). In contrast, grip strength, motor 
performance, and balance analyses at P18 showed no significant difference between treated and 
untreated SMA mice (Supplemental Figure 1). Collectively, the significant increase in lifespan, 
birth to peak weight gain, and improved motor performance indicate that scAAV9-STMN1 
treatment ameliorated the SMA phenotype in SMA mice.   
 
scAAV9-STMN1
 
treatment increases STMN1 protein expression without altering 
SMN protein levels. 
To confirm expression of the vector-derived transgene, STMN1 protein expression in brain 
tissue and spinal cord were analyzed by western blot at P18. In brain, western blot analysis 
demonstrated a 1.5-fold increase above untreated samples (Figure 4A). In spinal cord, western 
blot revealed no increase in STMN1 expression after treatment (Figure 4B). However, 
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immunohistochemistry analysis of spinal cord sections demonstrated that STMN1 expression 
was dramatically upregulated in motor neuron cell bodies (Figure 4C). Moreover, STMN1 
expression extended to dendrites and axons of motor neurons in scAAV9-STMN1 treated animals 
compared to untreated SMA and unaffected controls (Figure 4C). Since we were observing a 
positive impact upon the SMA phenotype, we wanted to confirm that SMN levels were not 
increased in scAAV9-STMN1 treated animals. Using the same tissues from the STMN1 blots, 
SMN levels were determined to be unchanged in both brain and spinal cord tissue 
(Supplementary Figure 2). These data demonstrate that in scAAV9-STMN1 treated animals, the 
improvement in the SMA phenotype occurred independent of SMN modulation and that STMN1 
can reduce disease severity in intermediate SMA mice.  
 
scAAV9-STMN1 treatment improves NMJ pathology in highly vulnerable muscles. 
Differentially vulnerable motor neurons in SMA mouse models were defined by the level of 
pathology present at the NMJ (32, 37). To determine if STMN1 improved NMJ pathology in 
treated SMA mice, P18 muscles were analyzed by immunofluorescence staining of vulnerable 
(transversus abdominis, rectus abdominis, and external oblique), and resistant (levator auris 
longus (rostral), auricularis superior, and abductor auris longus) muscle groups (37, 43). 
Antibodies against neurofilament heavy (NF-H) and synaptic vesicle protein 2 (SV2) were used 
to label the axon and pre-synaptic terminals, while alexa-594 conjugated alpha-bungarotoxin was 
used to label the motor endplate. Representative images of each muscle were taken and analyzed 
for denervation. To score the degree of pathology, we assessed the state of innervation for each 
terminal: 1) complete overlap between axon terminal and the endplate indicated of full 
innervation; 2) partial overlap indicated partial innervation; and 3) empty endplates indicated full 
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denervation (Figure 5A). As expected, control unaffected muscles showed no defects in NMJ 
innervation (Figure 5A, left panel) while untreated SMA muscles displayed evidence of partially 
and fully denervated endplates (Figure 5A, middle panel). In contrast, STMN1 treated SMA 
tissues showed a decrease in the frequency of denervated endplates compared to untreated SMA 
tissues (Figure 5A, right panel). Quantification of NMJ innervation profiles showed that treated 
SMA mice contained significantly more fully innervated NMJs in highly vulnerable muscles, 
including the transversus abdominis, rectus abdominis, and external oblique muscles compared 
to untreated SMA mice (Figure 5A-D). Moreover, NMJ innervation profiles of resistant muscle 
groups were not changed in STMN1 treated SMA mice compared to untreated SMA mice (Figure 
5E-G), demonstrating that while improvements are observed in vulnerable populations, there was 
no significant impact upon muscles that were already resistant to disease development. 
    
Treatment with STMN1 improves ventral horn (L3-L5) motor neuron pathology. 
To further understand how STMN1 improved the SMA phenotype, P18 lumbar spinal cords were 
cross-sectioned and immuno-stained with Nissl stain (neurotrace) to label all neuronal cells and 
with ChAT to detect motor neuron cell bodies. As expected, a significant difference was 
observed in the average number of motor neuron cell bodies per 16µm section between wildtype 
(Figure 6A, left panel) and untreated SMA mice (Figure 6A, middle panel). Consistent with the 
NMJ data, STMN1-treated SMA samples showed an increase in motor neuron cell body numbers 
per section compared to untreated SMA mice (Figure 6A right panel, B). Similarly, 
morphological measurements of cell bodies within the L3-L5 region of the spinal column 
revealed that STMN1 treated SMA neurons had a significant increase in cell body area (Figure 
6C) and perimeter (Figure 6D) compared to untreated SMA neurons. Overall, STMN1 treatment 
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resulted in an increase in motor neuron cell body number as well as improved motor neuron cell 
morphometrics that resembled those of unaffected control neurons. 
 
AAV9-STMN1 restored microtubule networks in ventral spinal cord motor neurons 
in SMA mice.   
Neuronal cell body morphology is dictated by the cells’ cytoskeleton networks, which are made 
up of microtubules, neurofilaments, and microfilaments. As the best described function of 
STMN1 is to promote microtubule depolymerization (42), we investigated whether STMN1 
treatment was functionally impacting microtubule networks surrounding neuronal cell bodies. 
Spinal cords from all treatment groups at P18 were cross-sectioned and immunostained using 
antibodies against III-tubulin to label microtubules, and Nissl stain (neurotrace) to label 
neuronal cell bodies. Super-resolution confocal imaging showed detection of discernable 
filamentous networks in unaffected spinal cords (Figure 7A, left panel). However, filamentous 
networks were obviously reduced in untreated SMA spinal cords (Figure 7A, middle panel). 
Interestingly, an improvement in the filamentous nature of the tubulin networks was observed in 
STMN1 treated SMA spinal cords. Filament microtubule density quantification revealed a 
significant increase in filament density in STMN1 treated spinal cords over both unaffected 
controls and untreated SMA spinal cords (Figure 7B). These analyses showed that STMN1 
treatment induced a robust restoration of filamentous tubulin networks and correction of 
phenotype at the cellular level in spinal cords of SMA mice.   
 
STMN1 treatment does not alter microtubule stability in SMA mice.   
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Microtubules undergo several posttranslational modifications that affect cytoskeleton dynamics 
(44). Microtubule acetylation is a microtubule posttranslational modification correlated with 
microtubule stability (45, 46). To investigate whether microtubule stability was affected by 
STMN1 treatment, we analyzed the levels of acetyl--tubulin expression in nervous tissue. 
Immunoblots from P18 brain homogenate showed no detectable change in -tubulin levels 
between STMN1-treated SMA tissue compared to untreated SMA and healthy controls (Figure 
8A). Similarly, no change in acetylated--tubulin was detected at P18 between any of the 
cohorts (Figure 8B). Interestingly, immunoblot quantifications from P18 spinal cord homogenate 
showed a slight, but statistically significant, decrease in -tubulin levels in untreated SMA spinal 
cord compared to unaffected controls. However, in STMN1 treated SMA spinal cord the levels of 
-tubulin were restored to those of unaffected controls (Figure 8C). Similarly, immunoblots for 
acetylated--tubulin showed significantly reduced levels in untreated SMA tissue, but in STMN1 
treated SMA tissues these levels were restored to unaffected levels (Figure 8D). Given that 
restoration of acetylated--tubulin levels mirrors the restoration of -tubulin levels in STMN1 
treated SMA spinal cords, these results indicate that STMN1 treatment does not affect 
microtubule stability, but restores overall -tubulin to unaffected control levels.   
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Discussion 
The search for SMA therapeutics has resulted in the development SpinrazaTM and Zolgensma, 
the only approved SMA drugs, and a significant pipeline with several exciting compounds that 
are currently in clinical trials (47). A significant area of emphasis in the SMA field is to expand 
therapeutic options to either enhance efficacy of existing SMN-dependent therapeutics with the 
goal of increasing the number of patients who respond to drugs. The severity of SMA has so far 
indicated that there is a relatively short therapeutic window to achieve a maximal effect, 
however, adjunctive or combinatorial strategies may expand this window, thereby increasing the 
number and the types of patients that respond to drugs. (26-29, 48-54).  
Transcriptomic analyses can generate vast amounts of data. However, a significant hurdle 
often revolves around narrowing the data set and identifying functionally relevant candidates. To 
identify STMN1 and other putative targets, a prior RNAseq analysis was performed between 
resistant and vulnerable neuronal populations in a SMA mouse model (37). These results were 
subsequently cross-referenced against similar data sets generated from resistant/vulnerable 
neuronal populations in other disease models, including ALS, SBMA, and SMA (36, 38, 39, 41). 
In each instance, Stmn1 was shown to be downregulated in the vulnerable neurons, suggesting 
that an increase in Stmn1 could provide protection from disease development. Given the roles of 
STMN1 in cellular functions, such as cell growth, motility, and intracellular transport, it had the 
potential to be a significant disease modifier (55). An important proof-of-concept for this 
approach was whether or not STMN1 would improve the NMJ pathology since this was the 
initial basis for identification in the resistant versus susceptible neuronal populations (31, 37). 
Consistent with this notion, STMN1 significantly reduced NMJ pathology in susceptible neurons 
in SMA mice. Moreover, our data indicate that vector-mediated delivery of STMN1 improved the 
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SMA phenotype, reduced motor neuron cell body pathology, and also improved microtubule 
filament networks. Further studies will be required to determine if improved microtubule 
networks directly correlate with improved motor neuron survival, and thus improved SMA 
phenotype. Importantly, delivery of STMN1 did not alter SMN protein expression in SMA mice, 
demonstrating that the improvement in phenotype involves a mechanism independent of an 
increase in SMN function.  
This work demonstrates that the strategy utilized for identifying SMA disease modifiers 
is possible through cross-disease transcriptomic analysis and validates its potential use in other 
genetic diseases, in particular those disease models that were utilized in the cross-referencing 
analysis: ALS and SBMA. Additionally, investigating the effectiveness of the remaining 
potential genetic modifiers identified in the cross-disease screen (41) would further validate the 
utility of this genetic analysis to identify functionally relevant disease modifying genes. To date, 
two of the genes identified in the cross-disease screen, STMN1 and alpha-synuclein have been 
evaluated in similar experimental contexts and are capable of significantly improving the SMA 
phenotype in intermediate SMA mice. In particular, each of these genes improves the NMJ 
pathology, an important consideration as these factors were identified in large part due to 
aberrant NMJ structures and maturation. Collectively, these two genetic modifiers may not be 
restricted to functioning solely within the SMA context, but may be useful in a broader disease 
context of neurodegeneration and neuropathology.  
Our data are consistent with previous reports showing that deletion of Stmn1 in mice 
leads to reduced nerve conduction velocity and central and peripheral axon degeneration 
attributed to disorganized microtubule networks (56, 57). Our studies demonstrate that STMN1 
significantly improved microtubule filamentous networks, possibly through increased 
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microtubule turnover, which directly influences cellular morphology growth and prevent motor 
neuron cell death. In contrast to the positive impact that we observed with Stmn1, another report 
showed that in a severe SMA mouse, Stmn1 levels were slightly elevated in spinal cord extracts 
(58). While homozygous deletion of Stathmin did not improve survival or the SMA phenotype 
(58), a hemizygous Stmn/SMA model showed improvements in NMJ pathology and a reduction 
in neuroinflammation (58). These differences could be attributed to the fact that the original 
tissues analyzed were laser-captured motor neuron cell bodies compared to the total cellular 
extract of the spinal cord, as well as that each study utilized very different mouse models. Taken 
together our data show that in an intermediate mouse model of SMA, overexpression of STMN1 
significantly reduced the SMA pathology and extended survival without altering SMN 
expression. Thus, STMN1 could be a candidate for combinatorial therapeutic approaches in the 
future.  
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Materials and Methods 
Animals, animal procedures, and injection 
Intermediate Smn
2B/- 
mouse model of SMA and healthy littermate Smn
2B/+ 
controls, referred to 
herein as, SMA and unaffected, respectively. Smn
2B/- 
mice of the C57/BL6 background were a 
gift from Dr. Rashmi Kothary at the University of Ottawa, Canada. Smn
2B/2B 
and Smn
+/- 
mice 
were kept as separate colonies, bred and genotyped as previously described (59).  
All animal procedures were carried out in accordance with procedures approved by NIH 
and MU animal Care and Use Committee. Smn
2B/- 
animals were genotyped at P1 according to the 
genotyping procedure previously described (59). Mice underwent intracerebroventricular (ICV) 
(53, 60, 61) injection on PND 2 1.0x10
11
 scAAV9-STNM1 viral genomes. At PND18, mice were 
anesthetized with 2.5% isoflurane and then perfused transcardially with cold 0.1M PBS (pH=7.4) 
followed by 4% paraformaldehyde in PBS. Mice were post-fixed for 48 hours at 4°C in 4% PFA. 
After post-fixing, animals were placed in 0.1M PBS and stored at 4 °C until used for spinal cord 
dissection. For NMJ analyses the mice were sacrificed with 2.5% isoflurane and muscles were 
dissected fresh, fixed for 20 min in 4% FPA at room temp, and stored in PBS until stained. 
 
Generation of scAAV9-STMN1 virus 
To induce overexpression of STMN1 we utilized a vector-based delivery system. Self-
complimentary AAV has been used in several disease models to induce a robust and rapid trans-
gene expression. We utilized self-complimentary scAAV9 vector to induce overexpression of 
STMN1 in a wide variety of cells. Chicken--actin (CBA) was used to drive the ubiquitous 
expression of STMN1 along with an optimized intron within the 5’ leader sequence as well as a 
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synthetic polyA site (Supplementary Figure 3). Viral particles were generated, purified and 
delivered via intracerebroventricular injection as previously described (62, 63). 
 
Motor performance tests 
Motor function was assayed by time-time-to right (TTR) assay from PND7, time at which 
unaffected controls begin to turn themselves over. Each pup was turned on its back and the time 
it takes to for them to turn over and stabilize on all four paws was recorded with a maximum 
attempt time of 60s. The time to right was measured (s) every day from PND6 to PND25 and 
averages were calculated for each treatment per day. Motor activity and coordination were 
measured using a rotarod treadmill for mice (IITC Rotarod Series 8, IITC Life Science, CA) with 
gradual speed acceleration from 0 to 40 rpm over 5 min. At P20 pups were trained to balance and 
walk on a 3¾ inch diameter drum and the time, and distance it took for the mice to fall off were 
measured and averaged from 3 separated trials with at least 20 min of rest between trial. 
Averages for each metric were obtained for each treatment. For grip strength analysis a grasping 
response test was used. At P20 each animal was placed on a wire mesh (1-cm
2 
grids) that is 
attached to a force transducer (Bioseb). The animals were allowed to grasp the mesh, then, 
gently, the animal was pulled horizontally from the tail until grip was lost. The maximum force 
in grams (g) was recorded and averaged for each mouse from 5 separate trials. Averages per 
treatment were calculated and compared.  
 
Western blots  
For western blot analyses, brain and spinal cords were harvested at P18 and immediately flash 
frozen in liquid nitrogen. Tissue was then lysed using JLB buffer [50 mM Tris pH=8.0, 150 mM 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz188/5540981 by U
niversity of Edinburgh user on 01 August 2019
 17 
NaCl, 10% Glycerol, 20 mM NaH2PO4, 50 mM NaF, 2mM EDTA, 5 mM NaVO3] supplied 
with cOmpleteTM, Mini Protease Inhibitor Cocktail (Roche). Following SDS-PAGE, protein 
was transferred to Immobilon®-P transfer membrane (MilliporeSigma) and probed with the 
following primary antibodies: anti-SMN (1:10,000; 610647, BD Transduction LaboratoriesTM), 
anti-Calnexin (1:2000; catalog C4731, anti-Tubulin (1:2000; catalog T7451, Sigma) anti-
acetylated-Tubulin (1:2000; catalog T6793, Sigma), and anti-STMN1(Ab-38) (1:1000; catalog 
SAB4300477, Sigma). Horseradish peroxidase-conjugated secondary antibodies were used 
(Jackson ImmunoResearch Laboratories). Immunoblots were visualized using (BioSpectrum® 
815 Imaging System, UVP, LLC). Densitometry analysis was performed using ImageJ software 
(NIH). 
 
Immunohistochemistry of neuromuscular junctions 
P18 untreated Smn
2B/+
 (unaffected), untreated Smn
2B/- 
(SMA), and scAAV9-STMN1 treated 
Smn
2B/-
 (SMA + STMN1) mice were used for NMJ pathology analyses. Whole mount 
preparations of previously fixed vulnerable (Transversus Abdominis (TVA), Rectus Abdominis 
(RA), and External Oblique (EO)) and resistant (Levator Auris Longus Rostral (LALR), 
Auricularis Superior (AS), Abductor Auris Longus (AAL)) muscle groups. Muscles were stained 
using specific antibodies, including anti-NF-H (1:2000; catalog AB5539, Chemicon, EMD 
Millipore), anti-synaptic vesicle protein 2 (SV2) (1:200, catalog YE269, Life Technologies). 
Acetylcholine receptors were labeled with Alexa Fluor 594–conjugated α-bungarotoxin (1:200; 
Life Technologies). Representative muscle images for were obtained using a laser scanning 
confocal microscope (x40 objective; Leica TCS SP8, Leica Microsystems Inc.). NMJ analysis 
was performed in a double blinded manner on at least 3 randomly selected fields of view per 
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muscle per mouse (x20 objective; Leica DM5500 B, Leica Microsystems Inc.). On average, each 
field of view contains between 30 and 50 NMJs that were used for endplate denervation. Images 
were analyzed using freely available Fiji Software (NIH). Endplates missing overlapping nerve 
terminal staining were considered fully denervated. Endplates with partial overlap were 
considered partially denervated and endplates with complete overlap were considered fully 
innervated.  
 
Motor neuron immunohistochemistry 
For motor neuron immunohistochemistry analyses, P18 untreated Smn
2B/+
, untreated Smn
2B/-
, and 
scAAV9-Stmn1 treated Smn
2B/-
 mice were used. The animals were sacrificed, perfused with ice-
cold 4% PFA, and post-fixed in 4% PFA for 24 hrs. at 4 °C. Spinal lumbar spinal cord was 
dissected, cryoprotected in 30% sucrose overnight. Cryoprotected spinal cords were embedded in 
OCT and cryosectioned at 16 µm thickness. Every tenth section from the L3-L5 spinal cord were 
collected and processed for immunohistochemistry. Sections were labeled with NeuroTrace Nissl 
and ChAT for motor neuron identification. Digital images were collected using a Leica DM5500 
B fluorescent microscope (Leica Microsystems Inc.) under 20X magnification. Motor neuron 
counts, cell diameter and perimeter measurements, were performed in a double-blinded manner 
from 16 sections per mouse. 
 
STMN1 localization  
For STMN1 immunohistochemistry, P18 spinal cord cross sections were obtained similarly to 
sections for motor neuron immunohistochemistry. Sections were stained using an anti-STMN1 
(Ab-38) (1:400; catalog SAB4300477) primary and anti-rabbit-alexa-594 secondary antibodies 
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to detect STMN1 localization. Sections were counter stained with Nissl stain (neurotrace) to 
identify motor neuron cell bodies. Images were obtained using a laser scanning confocal 
microscope (x40 objective; Leica TCS SP8, Leica Microsystems Inc.). 
  
Tubulin immunohistochemistry 
For tubulin immunohistochemistry, P18 spinal cord cross sections were obtained similarly to 
sections for motor neuron immunohistochemistry. Sections were stained using an antibody 
against β-III tubulin to detect microtubule filaments and Nissl stain (neurotrace) to identify 
motor neuron cell bodies. For quantifying microtubule density, 3 sections of 25µm
2
 were 
selected per spinal cord image at random (3 spinal cord images were used per animal) and using 
NeuronJ plugin(64) for ImageJ software (NIH), filament tracings were made to label all visible 
filaments in the selected image(Supplemental Figure 4). Then the tracings were counted in every 
25µm
2
 section and averaged for every genotype. The density of the tracings was calculated for 
every treatment and compared.  
 
Statistics 
All analyses were performed in a double-blinded manner and analyzed for statistical significance 
using GraphPad Prism version 7.0 (GraphPad Software Inc.). Survival was analyzed by a Log-
rank (Mantel-Cox) test. NMJ denervation, time to right and analyzed by two-way ANOVA with 
a Tukey’s post-hoc test for multiple comparisons and for ease of explanation only comparisons 
between fully innervated percentages were presented. Motor neuron cytological changes, 
microtubule network studies, western blots, grip strength, and rota rod studies were analyzed by 
a one-way ANOVA followed by a Tukey’s post-hoc test for multiple comparisons. 
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Figure 1. Strategy for identifying potential disease gene modifiers. 
The first step is to identify pools of motor neurons that are resistant and vulnerable to 
pathogenesis, which is determined by the vulnerability to denervation of target muscle fibers. 
Then by laser microdissection, motor neuron cell bodies are isolated and RNA is extracted from 
both pools. Transcriptomic analysis is performed on both pools and differentially expressed 
genes are identified and validated to generate a list of potential genes. These genes are then 
packaged into AAV9 virus and used to treat neonatal mouse models of the disease via ICV or IV 
injection. The effects of the gene modifier are then evaluated. 
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Figure 2. scAAV9-STMN1 treatment increases lifespan and birth to peak weight 
gain in SMA mice.  
Phenotypic analyses in SMA mice after ICV injection of 1.0x10
11
 scAAV9-STMN1 viral 
injection at P2. A) Survival was significantly increased (p < 0.001) in treated SMA mice 
compared to untreated SMA, healthy controls survived past 50 days. B)  Average weight gain 
was not different in treated SMA mice compared to untreated SMA up to day 25. C) Birth-to-
peak weight gain was significantly increased (p = 0.0486) in treated SMA mice compared to 
untreated SMA. D) Representative image showing health pup at P25 and improvement in overt 
appearance of treated SMN mice compared to untreated SMA mice. N=8, healthy control; n = 
13, untreated SMA; n = 17, treated SMA. Data expressed as mean  SEM. 
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Figure 3. Motor performance was improved in SMA mice following STMN1 
treatment.  
Time-to-right analysis in unaffected, untreated SMA and scAAV9-STMN1 treated SMA mice 
from P5 to P25. A) Percent of animals able to right at each specified timepoint shows an 
improvement of treated SMA mice compared to untreated SMA mice. B) Daily average time to 
right (s) shows that treated SMA mice are able to right significantly faster than untreated SMA 
mice from day P6 to P16 (p < 0.05). Moreover, from P17 to P20 treated SMA mice perform 
better than untreated SMA mice, although not statistically significant. Moreover, no statistical 
significance was found between unaffected and treated SMA mice from P17 to P20. Time to 
right comparisons were analyzed by a two-way-ANOVA followed by a Holm-Sidak post-hoc 
test for multiple comparisons. *, p < 0.05. N=8, healthy control; n = 13, untreated SMA; n = 17, 
treated SMA. Data expressed as mean ± SEM. 
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Figure 4. scAAV9-STMN1 treatment results in a significant increase in STMN1 
protein expression in peripheral tissues of SMA mice.  
Western blot analysis from brain tissue show that ICV injection of scAAV9-STMN1 leads to 
significant upregulation of STMN1 protein expression. A)  Western blots show upregulation of 
STMN1 protein in treated SMA mice compared to untreated SMA mice. B) Quantification of 
blots demonstrate a significant increase in STMN1 protein expression in treated SMA mice 
compared to untreated mice in peripheral tissues. Comparisons were analyzed by Student T-test. 
* p < 0.05. Data expressed as mean ± SEM. n = 3 animals per treatment.  
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Figure 5. scAAV9-STMN1 treatment improves NMJ pathology in vulnerable 
muscles of SMA mice.  
Immunohistochemistry analysis of NMJ innervation in vulnerable (transversus abdominis, rectus 
abdominis, and external oblique) and resistant (levator auris longus (rostral), auricularis superior, 
and abductor auris longus) muscles from unaffected, untreated SMA, and STMN1 treated SMA 
mice. Muscles were immunostained to label the axon (NF-H), axon terminal (SV), and endplate 
(AChRs). A) Representative images of PND18 transversus abdominis and rectus abdominis 
(vulnerable) muscles showing reduced frequency of denervated endplates in scAAV9-STMN1 
treated SMA mice (right panel) compared to untreated SMA mice (middle panel). Unaffected 
controls show no denervated endplates (left panel). Maximum projection confocal microscope 
images taken at 20X magnification.  White arrows point to the location of denervated endplates. 
B, C, and D) Quantification of NMJ denervation showing percentages of fully innervated, 
partially innervated, and fully denervated endplates in vulnerable muscles. E, F, and G) 
Quantification of NMJ denervation in resistant muscles showing percent fully innervated, 
partially innervated, and fully denervated NMJs.  Denervation analysis shows that STMN1 
treatment increases frequency of fully innervated endplates in SMA vulnerable muscles without 
affecting innervation of resistant muscles. For ease of presentation only statistical comparisons 
of fully innervated NMJ percentages are presented. Data analyzed by a 2-way ANOVA followed 
by a Tuckey’s post-hoc test for multiple comparisons. Data expressed as mean ± SEM.  **** p < 
0.0001, *** p < 0.001, n.s. = not significant. n = 3 animals per treatment. 
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Figure 6. scAAV9-STMN1 treatment prevents motor neuron cell body pathology in 
SMA mice.  
Cytological analysis of motor neuron cell body in L3-L5 spinal cord from PND18 treatment 
groups. A) Representative images of unaffected (left panel), untreated SMA (middle panel), and 
treated SMA (right panel) lumbar motor neurons immunostained with Nissl stain (neurotrace) to 
label neuronal cell bodies and ChAT to label specifically motor neurons. ChAT stain revealed an 
increased number of motor neurons in STMN1 treated SMA compared to untreated SMA mice. 
Fluorescent microscope images taken at 40x magnification. B) Quantification of motor neuron 
cell bodies showed a significant increase in cell numbers in STMN1 treated SMA mice compared 
to untreated SMA. However, STMN1 treated motor neuron cell numbers were still significantly 
lower than unaffected healthy controls. C) Morphometric analysis showed a significant 
improvement in motor neuron cell body area (µm
2
) of STMN1 treated SMA mice compared to 
untreated SMA mice. D) Analysis of cell body perimeter also showed significant improvement in 
SMTN1 treated SMA motor neurons as compared to untreated SMA. However, these 
improvements were still significantly lower than unaffected control. Data were analyzed by a 
one-way ANOVA followed by a Tukey’s post-hoc test for multiple comparisons. Data expressed 
as mean ± SEM. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, n.s. = not significant. n 
= 3 animals per treatment (n > 400, cells measured per treatment). 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz188/5540981 by U
niversity of Edinburgh user on 01 August 2019
 43 
 
 
 
 
 
 
 
 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz188/5540981 by U
niversity of Edinburgh user on 01 August 2019
 44 
Figure 7. scAAV9-STMN1 treatment restores microtubule filamentous networks in 
SMA mice. 
 Tubulin filament immunohistochemistry from L3-L5 spinal cords of treatment groups. A)  
Representative images of lumbar spinal cord ventral horn motor neurons stained with Nissl stain 
(neurotrace) and anti-BIII-tubulin antibodies conjugated to Alexa fluor-594 to label microtubule 
filaments. Unaffected control tissues showed distinct filamentous networks (left panel), which 
were absent in untreated SMA ventral horn spinal cords (middle panel). STMN1 treatment 
restored filamentous networks in SMA lumbar spinal cords to a greater extent compared to 
unaffected controls. Maximum projection high resolution confocal microscope images taken at 
63x magnification. B) Quantifications of filaments per 25µm
2
 showed a significant increase in 
filament density in treated SMA spinal cord compared to untreated and unaffected controls. Data 
were analyzed by a one-way ANOVA followed by a Tukey’s post-hoc test for multiple 
comparisons. Data expressed as mean ± SEM. **** p < 0.0001, ** p < 0.01, * p < 0.05, n.s. = 
not significant.  
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Figure 8. scAAV9-STMN1 treatment restores microtubule levels without affecting 
microtubule stability in spinal cord of SMA mice.  
Western blot analyses of tubulin expression and tubulin stability in brain and spinal cord of 
PND8 unaffected, untreated SMA and STMN1 treated SMA mice. A and B) Protein extracts 
from brain immunoblotted with antibodies specific for -tubulin (A, top) and acetylated--
tubulin (B, top) and blot quantifications showing no difference in -tubulin (A, bottom) or 
acetylated--tubulin (B, bottom) expression in untreated SMA or treated SMA mice compared to 
unaffected controls. C and D) Protein extracts form lumbar spinal cord immunoblotted for -
tubulin (C, bottom) and acetylated--tubulin (D, top) and quantifications showed significant 
decrease in -tubulin (C, bottom) and acetylated--tubulin (D, bottom) in untreated SMA spinal 
cords compared to unaffected controls. Moreover, quantifications show restoration of both -
tubulin and acetylated--tubulin (C and D, bottom) in STMN1 treated SMA spinal cords 
compared to unaffected controls. Data were analyzed by a one-way ANOVA followed by a 
Tukey’s post-hoc test for multiple comparisons. Data expressed as mean ± SEM. ** p < 0.01, * p 
< 0.05, n.s. = not significant. n = 3 animals per treatment.  
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz188/5540981 by U
niversity of Edinburgh user on 01 August 2019
 47 
 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz188/5540981 by U
niversity of Edinburgh user on 01 August 2019
